Payment overview · 2025
General Payments
$210.06
3 reported records · 3 companies
Healthcare provider profile · identity verified
Yohana M Cabrera
Allopathic & Osteopathic Physicians|Internal Medicine · MIAMI, FL · NPI 1033143185
Verified facts
What the public records show
CMS Open Payments records show Yohana M Cabrera received $210.06 in general payments during 2025 across 3 reported records.
Boston Scientific Corporation accounted for 82.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $173.13 | 82.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.11 | 10.5% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $14.82 | 7.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $210.06 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $173.13 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.11 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.11 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.11 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $14.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 26 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
26 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 1134 | 260 |
| Gabapentin | Gabapentin | 750 | 125 |
| Atorvastatin Calcium | Atorvastatin Calcium | 678 | 198 |
| Levothyroxine Sodium | Levothyroxine Sodium | 486 | 131 |
| Omeprazole | Omeprazole | 460 | 158 |
| Metformin Hcl | Metformin Hcl | 436 | 103 |
| Amlodipine Besylate | Amlodipine Besylate | 434 | 122 |
| Metoprolol Succinate | Metoprolol Succinate | 399 | 110 |
| Pantoprazole Sodium | Pantoprazole Sodium | 384 | 130 |
| Xarelto | Rivaroxaban | 383 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 369 | 108 |
| Hydrochlorothiazide | Hydrochlorothiazide | 334 | 98 |
| Warfarin Sodium | Warfarin Sodium | 331 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 275 | 78 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 275 | 114 |
| Furosemide | Furosemide | 263 | 68 |
| Atenolol | Atenolol | 244 | 66 |
| Alendronate Sodium | Alendronate Sodium | 234 | 83 |
| Simvastatin | Simvastatin | 227 | 63 |
| Sildenafil Citrate | Sildenafil Citrate | 194 | 33 |
| Metformin Hcl Er | Metformin Hcl | 189 | 52 |
| Folic Acid | Folic Acid | 188 | 60 |
| Metoprolol Tartrate | Metoprolol Tartrate | 183 | 49 |
| Dapagliflozin | Dapagliflozin Propanediol | 182 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 173 | 30 |
| Lisinopril | Lisinopril | 173 | 53 |
| Temazepam | Temazepam | 171 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 170 | 55 |
| Mupirocin | Mupirocin | 169 | 81 |
| Famotidine | Famotidine | 164 | 55 |
| Sertraline Hcl | Sertraline Hcl | 156 | 52 |
| Montelukast Sodium | Montelukast Sodium | 152 | 37 |
| Alprazolam | Alprazolam | 140 | 20 |
| Benzonatate | Benzonatate | 139 | 68 |
| Carvedilol | Carvedilol | 136 | 39 |
| Lansoprazole | Lansoprazole | 124 | 31 |
| Celecoxib | Celecoxib | 121 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 118 | 54 |
| Ibuprofen | Ibuprofen | 113 | 31 |
| Mirtazapine | Mirtazapine | 113 | 49 |
| Donepezil Hcl | Donepezil Hcl | 112 | 40 |
| Diclofenac Sodium | Diclofenac Sodium | 111 | 38 |
| Hydrocortisone | Hydrocortisone | 107 | 38 |
| Memantine Hcl | Memantine Hcl | 105 | 28 |
| Clonazepam | Clonazepam | 102 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 101 | 37 |
| Glipizide Er | Glipizide | 101 | 30 |
| Naproxen | Naproxen | 99 | 36 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 97 | 35 |
| Buspirone Hcl | Buspirone Hcl | 96 | 39 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 95 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 93 | 25 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 92 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 89 | 21 |
| Loperamide | Loperamide Hcl | 88 | 30 |
| Lorazepam | Lorazepam | 76 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 75 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 28 |
| Finasteride | Finasteride | 72 | 18 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 71 | 18 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 70 | 14 |
| Nyamyc | Nystatin | 69 | 23 |
| Spironolactone | Spironolactone | 69 | 19 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 67 | 16 |
| Synjardy | Empagliflozin/Metformin Hcl | 67 | 17 |
| Silver Sulfadiazine | Silver Sulfadiazine | 66 | 21 |
| Allopurinol | Allopurinol | 64 | 18 |
| Irbesartan | Irbesartan | 64 | 14 |
| Lactulose | Lactulose | 63 | 21 |
| Nystatin | Nystatin | 62 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | 26 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 53 | 13 |
| Potassium Chloride | Potassium Chloride | 52 | 12 |
| Nitroglycerin | Nitroglycerin | 51 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 13 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 47 | 47 |
| Dutasteride | Dutasteride | 47 | 15 |
| Glipizide | Glipizide | 47 | 16 |
| Ibandronate Sodium | Ibandronate Sodium | 46 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 46 | 15 |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 43 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 41 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 41 | suppressed |
| Nifedipine Er | Nifedipine | 41 | 12 |
| Pregabalin | Pregabalin | 40 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 40 | 12 |
| Glimepiride | Glimepiride | 39 | 13 |
| Meloxicam | Meloxicam | 38 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 38 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 32 |
| Theophylline Er | Theophylline Anhydrous | 36 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | 11 |
| Tramadol Hcl | Tramadol Hcl | 35 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 32 | 11 |
| Gemfibrozil | Gemfibrozil | 32 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 32 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 31 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | 14 |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 30 | 13 |
| Eliquis | Apixaban | 29 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 29 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 26 | 26 |
| Alogliptin | Alogliptin Benzoate | 26 | suppressed |
| Ketoconazole | Ketoconazole | 26 | suppressed |
| Pentoxifylline | Pentoxifylline | 26 | suppressed |
| Sotalol | Sotalol Hcl | 25 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 24 | 12 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 23 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 23 | 14 |
| Dapagliflozin-Metformin Er | Dapaglifloz Propaned/Metformin | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Comfort Ez Insulin Syringe | Syringe And Needle,insulin,1ml | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | 12 |
| Erythromycin | Erythromycin Base | 12 | 11 |
| Estradiol | Estradiol | 12 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $210.06 · 3 records | Boston Scientific Corporation | ABRYSVO, COMIRNATY, ImmunoCAP, PREVNAR 20, WATCHMAN FLX | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error